Iridex vs RxSight
IRIX and RXST side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRIX and RXST compare
RxSight is the larger company, worth 18 times as much as Iridex ($224M against $12.5M).
Iridex grew revenue faster over the last twelve months (3.7% versus −13.2% for RxSight).
Iridex keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −36.8% at RxSight.
RxSight scores higher on the StockData Score (10 against 7 for Iridex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRIX | RXST |
|---|---|---|
| Size and price | ||
| Market cap | $12.5M | $224M |
| Share price | $0.710 | $5.38 |
| Change, 1 year | −40.4% | −47.4% |
| Change, 5 years | −90.7% | −60.2% |
| Beta (5Y) | 0.94 | 1.12 |
| Employees | 93 | 461 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 1.8× |
| P/B | 3.4× | 0.8× (better) |
| FCF yield | −16.0% | −12.1% (better) |
| Fair value | – | $20.63 |
| Margin of safety | – | 73.9% |
| Growth | ||
| Revenue growth (TTM) | 3.7% (better) | −13.2% |
| Revenue growth, 5Y average | 7.7% | 55.7% (better) |
| Profitability | ||
| Gross margin | 35.9% | 77.5% (better) |
| Operating margin | −5.4% (better) | −43.2% |
| Net margin | −6.9% (better) | −36.8% |
| FCF margin | −3.9% (better) | −21.3% |
| Return on equity | −73.1% | −17.3% (better) |
| Return on invested capital | – | −82.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −3674.3× |
| Current ratio | 1.82 | 4.07 (better) |
| Altman Z-score | −2.49 | −0.55 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.89% |
| Shareholder yield | 0.00% (better) | −0.89% |
| Ownership | ||
| Held by institutions | 12.4% | 99.6% |
| Held by insiders | 76.1% | 5.4% |
| Insider net buying, 12 months | $536K (better) | −$118K |
| Short interest, % of float | 0.94% | 9.2% |
Go deeper
- IRIX stock overview
- IRIX income statement
- IRIX valuation and score
- RXST stock overview
- RXST income statement
- RXST valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.